Charles River Laboratories International, Inc. (CRL) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Total · absolute moveSwitch to Alpha · NYSE
Charles River Laboratories International, Inc. (CRL) stock forecast summary
On Oct. 16, 2026, CRL is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 5172 stocks scored that day.
Charles River Laboratories International, Inc. is a large-cap company with a market capitalization of $14.33B. It ranks number 4 by market capitalization among the 15 Services-Commercial Physical & Biological Research issuers in our coverage with a current forecast.
For CRL, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 61.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 41.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +5.0%, buy ≥ +3.4%, sell < +1.8%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, CRL included.
Follow CRL freeCRL price chart and AI forecast
How CRL ranks among 5172 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Charles River Laboratories International, Inc. (CRL) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Commercial Physical & Biological Research peers listed below that report each metric.
Valuation & Market
| Metric | CRL | Rank |
|---|---|---|
| Market Cap | $14.33B | 4/15 |
| P/B Ratio | 5.05x | 4/10 |
| EPS | $-4.00 | – |
| Book Value/Share | $59.48 | – |
| Revenue/Share | $83.77 | – |
| FCF/Share | $7.76 | – |
Profitability & Margins
| Metric | CRL | Rank |
|---|---|---|
| ROE | -8.4% | 5/9 |
| ROA | -3.2% | 5/11 |
| ROIC | 1.4% | 8/11 |
| Operating Margin | 2.2% | 6/13 |
| Net Margin | -6.0% | 5/10 |
| EBT Margin | -0.9% | 6/13 |
| Tax Rate | -152.4% | – |
The effective tax rate is outside the normal band, which points to a large non-recurring tax item in the trailing twelve months; headline net income, net margin and P/E are affected by it.
Financial Health
| Metric | CRL | Rank |
|---|---|---|
| Current Ratio | 1.35x | 6/16 |
| Quick Ratio | 1.04x | 5/6 |
| D/E Ratio | 1.64x | 5/11 |
| Financial Leverage | 2.65x | 5/10 |
| Interest Coverage | 5.0x | 4/13 |
| Working Capital | $394M | 2/15 |
Cash Flow
| Metric | CRL | Rank |
|---|---|---|
| Operating Cash Flow | $582M | 5/15 |
| Free Cash Flow | $371M | 3/7 |
| Capital Spending | -$212M | 6/7 |
| OCF Growth YoY | -26.1% | 5/5 |
| FCF Growth YoY | -35.9% | – |
| FCF/Sales | 9.3% | 4/8 |
| CapEx/Sales | 5.3% | 3/8 |
Operational Efficiency
| Metric | CRL | Rank |
|---|---|---|
| Asset Turnover | 0.53x | 6/8 |
| Receivables Turnover | 5.6x | 4/7 |
| Fixed Assets Turnover | 2.7x | 7/9 |
| Days Sales Outstanding | 65 days | 4/7 |
Income Statement
| Metric | CRL | Rank |
|---|---|---|
| Total Revenue | $4.00B | 3/8 |
| Operating Income | $90M | 5/15 |
| Net Income | -$238M | 12/12 |
| SG&A Expense | $762M | 4/12 |
Dividend & Shareholder Information
| Metric | CRL | Rank |
|---|---|---|
| Shares Outstanding | 48M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $1.53B | 20.3% of assets |
| Cash & Short-term Investments | $192M | 2.5% of assets |
| Accounts Receivable | $712M | 9.4% of assets |
| Inventory | $346M | 4.6% of assets |
| Total Liabilities | $4.64B | 61.7% of assets |
| Short-term Debt | $994M | 13.2% of assets |
CRL quarterly financials and insider trading
Charles River Laboratories International, Inc. (CRL) industry peers
Companies classified under the same SEC industry code as Charles River Laboratories International, Inc. (Services-Commercial Physical & Biological Research): 16 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| CRL Charles River Laboratories International, Inc. | ▶ | $14.33B |
| IQV Iqvia Holdings Inc. | ▼ | $45.37B |
| INCY Incyte Corp | ▼ | $22.20B |
| MEDP Medpace Holdings, Inc. | ▼ | $17.26B |
| ICLR Icon Plc | ▶ | $13.13B |
| ABSI Absci Corp | ▲ | $1.42B |
| OABI Omniab, Inc. | ▲ | $667M |
| NRC Nrc Health | ▶ | $446M |
| MXCT Maxcyte, Inc. | ▲ | $134M |
| ONMD Onemednet Corp | ▲ | $28M |
| VSBC Vitaspring Biomedical Co. Ltd. | ▼ | $7M |
| BIAF Bioaffinity Technologies, Inc. | ▼ | $5M |
| BUDZ Weed, Inc. | ▲ | $3M |
| ISPC Ispecimen Inc. | ▼ | $3M |
| FOXO Foxo Technologies Inc. | ▼ | $180K |
| CBIH Cannabis Bioscience International Holdings, Inc. | ▼ | N/A |
Where CRL sits on the market map
Charles River Laboratories International, Inc. (CRL) stock news
Loading...
Charles River Laboratories International, Inc. (CRL) stock forecast FAQ
What is the Charles River Laboratories International, Inc. (CRL) stock forecast?
On Oct. 16, 2026, CRL is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 5172 stocks scored that day.
How accurate are Charles River Laboratories International, Inc. stock predictions?
For CRL, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 61.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 41.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Charles River Laboratories International, Inc. forecasts updated?
Charles River Laboratories International, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Charles River Laboratories International, Inc.'s industry peers?
16 issuers in our coverage, CRL included, share the SEC industry code Services-Commercial Physical & Biological Research. The largest are: Iqvia Holdings Inc. (IQV), Incyte Corp (INCY), Medpace Holdings, Inc. (MEDP), Icon Plc (ICLR), Absci Corp (ABSI), Omniab, Inc. (OABI).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.